A Phase II, Multicenter, Open Label Study of Bintrafusp alfo (M7824) Monotherapy in Participants with Advanced, Unresectable Cervical Cancer with Disease Progression During or After Platinum-Containing Chemotherapy (EMD Serono MS200647-0017)
The main purpose of this study is to evaluate clinical efficacy and safety of bintrafusp alfa in participants with advanced, unresectable cervical cancer with disease progression during or after platinum-containing chemotherapy.